CN115010676A - 一种4,5-二甲基-3-氨基异噁唑的制备方法和应用 - Google Patents
一种4,5-二甲基-3-氨基异噁唑的制备方法和应用 Download PDFInfo
- Publication number
- CN115010676A CN115010676A CN202210503052.5A CN202210503052A CN115010676A CN 115010676 A CN115010676 A CN 115010676A CN 202210503052 A CN202210503052 A CN 202210503052A CN 115010676 A CN115010676 A CN 115010676A
- Authority
- CN
- China
- Prior art keywords
- dimethyl
- aminoisoxazole
- preparation
- intermediate compound
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VPANVNSDJSUFEF-UHFFFAOYSA-N 4,5-dimethyl-1,2-oxazol-3-amine Chemical compound CC=1ON=C(N)C=1C VPANVNSDJSUFEF-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000011734 sodium Substances 0.000 claims abstract description 9
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 9
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005695 Ammonium acetate Substances 0.000 claims abstract description 8
- 235000019257 ammonium acetate Nutrition 0.000 claims abstract description 8
- 229940043376 ammonium acetate Drugs 0.000 claims abstract description 8
- -1 sodium alkoxide Chemical class 0.000 claims abstract description 8
- 150000001879 copper Chemical class 0.000 claims abstract description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 16
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical group [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- 229940126062 Compound A Drugs 0.000 claims description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 7
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical group CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 2
- 229940124350 antibacterial drug Drugs 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000654 sulfafurazole Drugs 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 claims 2
- 229910021590 Copper(II) bromide Inorganic materials 0.000 claims 1
- 229940076286 cupric acetate Drugs 0.000 claims 1
- 229960003280 cupric chloride Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 239000003054 catalyst Substances 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 238000007363 ring formation reaction Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- IHXNSHZBFXGOJM-HWKANZROSA-N (e)-2-methylbut-2-enenitrile Chemical compound C\C=C(/C)C#N IHXNSHZBFXGOJM-HWKANZROSA-N 0.000 description 2
- WBAXCOMEMKANRN-UHFFFAOYSA-N 2-methylbut-3-enenitrile Chemical compound C=CC(C)C#N WBAXCOMEMKANRN-UHFFFAOYSA-N 0.000 description 2
- OIMRLHCSLQUXLL-UHFFFAOYSA-N 3-chlorobutan-2-one Chemical compound CC(Cl)C(C)=O OIMRLHCSLQUXLL-UHFFFAOYSA-N 0.000 description 2
- YJJQJSWYNHJPCB-UHFFFAOYSA-N C(CC)#N.[Na] Chemical compound C(CC)#N.[Na] YJJQJSWYNHJPCB-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/17—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and doubly-bound oxygen atoms bound to the same acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/26—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing hydroxy groups
- C07C47/263—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing hydroxy groups acyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
本发明公开了一种4,5‑二甲基‑3‑氨基异噁唑的制备方法和应用,以丁酮和甲酸酯为原料,在醇钠下缩合得到醛式结构中间体A,再和醋酸铵在铜盐催化剂下发生氧化反应得到氰基中间体B,然后再与盐酸羟胺进行环合反应得到4,5‑二甲基‑3‑氨基异噁唑。本发明与传统合成路线相比,缩短了合成步骤,具有合成简洁、操作简单、收率高的优点。
Description
技术领域
本发明属于药物合成技术领域,具体涉及一种4,5-二甲基-3-氨基异噁唑的制备方法和应用。
背景技术
现有技术中合成4,5-二甲基-3-氨基异噁唑的方法主要有以下几种:(1)中国专利CN110357830A报道了一种以2-甲基-2-丁烯腈和2-甲基-3-丁烯腈的混合物为起始原料,经过和DBU、液溴、甲醇钠、乙酰氨基肟等三步反应得到4,5-二甲基-3-氨基异噁唑的合成路线,但是该合成路线起始物料2-甲基-2-丁烯腈和2-甲基-3-丁烯腈的混合物较为难得,反应中还使用液溴到位反应物料,使用成本高,不利于反应控制和工业化放大生产;(2)美国专利US2430094A报道了由丙腈钠和乙酸乙酯缩合得到化合物B,然后再和盐酸羟胺反应得到4,5-二甲基-3-氨基异噁唑,但是该方法中的丙腈钠合成需要用到金属钠,合成条件不利于放大,所用金属钠存在较大的安全风险;(3)在文献Justus Liebigs Annalen derChemie,1978,p.1946-1962中,Kobler H.等人报道了一种由3-氯丁酮和氰化钠合成化合物B方法,在该方法中使用了剧毒性的氰化钠,而且反应收率偏低,而3-氯丁酮也是较为难得的原材料。鉴于此,有必要研究一种反应条件简单且产物收率高的4,5-二甲基-3-氨基异噁唑的制备方法。
发明内容
为解决现有技术的不足,本发明的目的在于提供一种反应条件简单且产物收率高的4,5-二甲基-3-氨基异噁唑的制备方法。
为了实现上述目标,本发明采用如下的技术方案:
一种4,5-二甲基-3-氨基异噁唑的制备方法,包括以下步骤:
S1、制备醛式中间体化合物A:在烧瓶中分别加入醇钠和有机溶剂,搅拌,缓慢滴加丁酮和甲酸酯的混合溶液,反应结束后得到中间体化合物A,反应方程式为:
S2、制备氰基中间体化合物B:在烧瓶中分别加入中间体化合物A、醋酸铵、铜盐和溶剂Ⅰ,搅拌,反应结束后得到中间体化合物B,反应方程式为:
S3、制备4,5-二甲-3-氨基-异噁唑:在烧瓶中加入盐酸羟胺和溶剂Ⅱ,缓慢滴加中间体化合物B,滴加完毕后,过滤得到4,5-二甲基-3-氨基异噁唑,反应方程式为:
优选地,前述步骤S1中,有机溶剂为甲苯或二甲苯,醇钠为甲醇钠或乙醇钠,甲酸酯为甲酸乙酯或甲酸甲酯。
优选地,前述步骤S1中,丁酮、甲酸酯和醇钠的摩尔比为(1~1.2):(1~1.2):1。
优选地,前述步骤S2中,铜盐为醋酸铜、氯化铜或溴化铜中的一种。
优选地,前述步骤S2中,中间体化合物A、醋酸铵和铜盐的摩尔比为1:(1.2~1.5):(0.05~0.15)。
优选地,前述步骤S2中,溶剂Ⅰ为二甲基亚砜,所述步骤S3中,溶剂Ⅱ为去离子水。
优选地,前述步骤S3中,中间体化合物B和盐酸羟胺的摩尔比为1:(1.2~1.5)。
一种用于制备4,5-二甲基-3-氨基异噁唑的中间体化合物A,具有以下结构式:
一种用于制备4,5-二甲基-3-氨基异噁唑的中间体化合物B,具有以下结构式:
4,5-二甲基-3-氨基异噁唑在制备抗菌药物磺胺异噁唑中的应用。
本发明的有益之处在于:本发明具有操作工艺简单、能耗低、生产成本低廉和适用范围广的优点,反应过程新颖,比常规的合成路线要短,工艺条件稳健性强,适合大规模制备4,5-二甲基-3-氨基异噁唑。
附图说明
图1是本发明的反应方程式;
图2是本发明中间体化合物B的HPLC图谱;
图3是本发明4,5-二甲基-3-氨基异噁唑的HPLC图谱;
图4是本发明4,5-二甲基-3-氨基异噁唑的IR图谱。
具体实施方式
以下结合附图和具体实施例对本发明作具体的介绍。
实施例1
S1、制备醛式中间体化合物A:在四口烧瓶中加入12.6g甲醇钠(0.25mol)和150ml甲苯,搅拌下升温至60~70℃,缓慢滴加19.5g丁酮(0.27mol)和20.0g甲酸乙酯(0.27mol)的混合溶液,滴加完毕后保温搅拌5h,反应结束后,降温至室温,抽滤,滤饼在真空下40℃烘干,得到中间体A为27.5g,收率为90%;
S2、制备氰基中间体化合物B:在四口烧瓶中加入27.5g中间体A(0.225mol)、20.8g醋酸铵(0.27mol)、2.2g醋酸铜(0.02mol)和100毫升二甲基亚砜(DMSO),搅拌下升温至60~70℃,保温反应8小时,反应结束后,降温至室温,过滤除去催化剂和不溶物盐,在滤液中加入水和乙酸乙酯,分相后得到乙酸乙酯层,蒸馏乙酸乙酯后得到得到21.4g中间体B,收率为85%,中间体化合物B的HPLC图谱见图2;
S3、制备4,5-二甲-3-氨基-异噁唑:在四口烧瓶中加入13.6g盐酸羟胺(0.196mol)和150ml水,控温在20~30℃,缓慢滴加20g中间体B(0.178mol),滴加完毕后,继续在保温3h,析出固体,过滤收集滤饼,真空下40~45℃干燥后得到4,5-二甲基-3-氨基异噁唑18.3g,收率为91%,4,5-二甲基-3-氨基异噁唑的HPLC图谱见图3,IR图谱见图4。
实施例2
S1、制备醛式中间体化合物A:在四口烧瓶中加入12.6g甲醇钠(0.25mol)和150ml甲苯,搅拌下升温至60~70℃,缓慢滴加21.7g丁酮(0.30mol)和22.2g甲酸乙酯(0.30mol)的混合溶液,滴加完毕后保温搅拌5h,反应结束后,降温至室温,抽滤,滤饼在真空下40℃烘干,得到中间体A为28.1g,收率为92%;
S2、制备氰基中间体化合物B:在四口烧瓶中加入27.5g中间体A(0.225mol)、19.2g醋酸铵(0.22mol)、2.0g醋酸铜(0.018mol)和100毫升DMSO,搅拌下升温至60~70℃,保温反应8小时,反应结束后,降温至室温,过滤除去催化剂和不溶物盐,在滤液中加入水和乙酸乙酯,分相后得到乙酸乙酯层,蒸馏乙酸乙酯后得到得到20.9g中间体B,收率为83%;
S3、制备4,5-二甲-3-氨基-异噁唑:在四口烧瓶中加入12.5g盐酸羟胺(0.18mol)、150ml水,控温在20~30℃,缓慢滴加19.5g中间体B(0.173mol),滴加完毕后,继续在保温3h,析出固体,过滤收集滤饼,真空下40~45℃干燥后得到4,5-二甲基-3-氨基异噁唑18.0g,收率为93%。
实施例3
S1、制备醛式中间体化合物A:在四口烧瓶中加入30g甲醇钠(0.555mol)和320ml甲苯,搅拌下升温至60~70℃,缓慢滴加42.0g丁酮(0.583mol)和43.6g甲酸乙酯(0.588mol)的混合溶液,滴加完毕后保温搅拌5h,反应结束后,降温至室温,抽滤,滤饼在真空下40℃烘干,得到中间体A为63.0g,收率为93%;
S2、制备氰基中间体化合物B:在四口烧瓶中加入50g中间体A(0.41mol)、36.3g醋酸铵(0.47mol)、3.0g醋酸铜(0.016mol)和200毫升DMSO,搅拌下升温至60~70℃,保温反应8小时,反应结束后,降温至室温,过滤除去催化剂和不溶物盐,在滤液中加入水和乙酸乙酯,分相后得到乙酸乙酯层,蒸馏乙酸乙酯后得到得到39.5g中间体B,收率为86%;
S3、制备4,5-二甲-3-氨基-异噁唑:在四口烧瓶中加入21.3g盐酸羟胺(0.307mol)、150ml水,控温在20~30℃,缓慢滴加30g中间体B(0.267mol),滴加完毕后,继续在保温3h,析出固体,过滤收集滤饼,真空下40~45℃干燥后得到4,5-二甲基-3-氨基异噁唑27.5g,收率为92%。反应方程式如下:
对比例
对比例的反应方程式如下:
在2L三口烧瓶加入式中DO所示混合物16.9g、二氯甲烷50ml,氮气保护下,加入DBU0.2g,保温在25℃反应16小时;然后冷却至0℃,滴加液溴10ml,并继续在室温下下保温反应16小时;反应结束后,加入50ml的20%的亚硫酸氢钠溶液,分层收集二氯甲烷相,水相再用二氯甲烷萃取一次,合并有机相,无水硫酸钠干燥后浓缩得到中间体D1;将D1中间体加入到反应瓶中,氮气保护下,加入甲醇40毫升,乙酰基羟胺12.6g,含有21.0g甲醇钠的甲醇溶液84g缓慢滴加到上述反应液中,反应控制在50℃左右,然后保温回流16小时,反应结束后,蒸干甲醇,加入10%NaH2PO4溶液90ml,调节pH至7~8,乙酸乙酯萃取3次(每次50ml),合并乙酸乙酯,50ml水洗一次,饱和食盐水水洗,无水硫酸钠干燥,浓缩,甲苯重结晶得到15.4g产品(理论收率23.3g),产品收率66%。
对实施例1~3中制备的中间体A、中间体B和4,5-二甲基-3-氨基异噁唑以及对比例中制备的4,5-二甲基-3-氨基异噁唑产物收率进行计算,结果见下表:
中间体A收率 | 中间体B收率 | 4,5-二甲基-3-氨基异噁唑收率 | 总收率 | |
实施例1 | 90% | 85% | 91% | 70% |
实施例2 | 92% | 83% | 93% | 71% |
实施例3 | 93% | 86% | 92% | 73% |
对比例 | NA | NA | NA | 66% |
由上表可知,本发明制备的4,5-二甲基-3-氨基异噁唑具有较高的收率,且反应条件简单。
以上显示和描述了本发明的基本原理、主要特征和优点。本行业的技术人员应该了解,上述实施例不以任何形式限制本发明,凡采用等同替换或等效变换的方式所获得的技术方案,均落在本发明的保护范围内。
Claims (10)
2.根据权利要求1所述的一种4,5-二甲基-3-氨基异噁唑的制备方法,其特征在于,所述步骤S1中,有机溶剂为甲苯或二甲苯,所述醇钠为甲醇钠或乙醇钠,所述甲酸酯为甲酸乙酯或甲酸甲酯。
3.根据权利要求1所述的一种4,5-二甲基-3-氨基异噁唑的制备方法,其特征在于,所述步骤S1中,丁酮、甲酸酯和醇钠的摩尔比为(1~1.2):(1~1.2):1。
4.根据权利要求1所述的一种4,5-二甲基-3-氨基异噁唑的制备方法,其特征在于,所述步骤S2中,铜盐为醋酸铜、氯化铜或溴化铜中的一种。
5.根据权利要求1所述的一种4,5-二甲基-3-氨基异噁唑的制备方法,其特征在于,所述步骤S2中,中间体化合物A、醋酸铵和铜盐的摩尔比为1:(1.2~1.5):(0.05~0.15)。
6.根据权利要求1所述的一种4,5-二甲基-3-氨基异噁唑的制备方法,其特征在于,所述步骤S2中,溶剂Ⅰ为二甲基亚砜,所述步骤S3中,溶剂Ⅱ为去离子水。
7.根据权利要求1所述的一种4,5-二甲基-3-氨基异噁唑的制备方法,其特征在于,所述步骤S3中,中间体化合物B和盐酸羟胺的摩尔比为1:(1.2~1.5)。
10.权利要求1所述的4,5-二甲基-3-氨基异噁唑在制备抗菌药物磺胺异噁唑中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210503052.5A CN115010676A (zh) | 2022-05-10 | 2022-05-10 | 一种4,5-二甲基-3-氨基异噁唑的制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210503052.5A CN115010676A (zh) | 2022-05-10 | 2022-05-10 | 一种4,5-二甲基-3-氨基异噁唑的制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115010676A true CN115010676A (zh) | 2022-09-06 |
Family
ID=83068933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210503052.5A Pending CN115010676A (zh) | 2022-05-10 | 2022-05-10 | 一种4,5-二甲基-3-氨基异噁唑的制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115010676A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003012603A (ja) * | 2001-07-04 | 2003-01-15 | Kao Corp | モノグリセリドの製造法 |
JP2003012630A (ja) * | 2001-06-26 | 2003-01-15 | Ube Ind Ltd | β−ケトニトリル誘導体の製法 |
US20040171863A1 (en) * | 2001-08-02 | 2004-09-02 | Ube Industries, Ltd. | Process for poducing beta-oxonitrile compound or alkali metal salt thereof |
CN101838263A (zh) * | 2009-03-18 | 2010-09-22 | 中国药科大学 | 具有心血管活性的苯并咪唑类衍生物、其制备方法及用途 |
-
2022
- 2022-05-10 CN CN202210503052.5A patent/CN115010676A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003012630A (ja) * | 2001-06-26 | 2003-01-15 | Ube Ind Ltd | β−ケトニトリル誘導体の製法 |
JP2003012603A (ja) * | 2001-07-04 | 2003-01-15 | Kao Corp | モノグリセリドの製造法 |
US20040171863A1 (en) * | 2001-08-02 | 2004-09-02 | Ube Industries, Ltd. | Process for poducing beta-oxonitrile compound or alkali metal salt thereof |
CN101838263A (zh) * | 2009-03-18 | 2010-09-22 | 中国药科大学 | 具有心血管活性的苯并咪唑类衍生物、其制备方法及用途 |
Non-Patent Citations (2)
Title |
---|
DOKIC, SLOBODAN 等: "Preparation of some pharmaceutical raw materials by using ion exchangers" * |
湖南医药工业研究院: "磺胺异噁唑合成方法综述" * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112125805B (zh) | 水溶性厚朴酚衍生物及和厚朴酚衍生物和其中间体的制备方法、和相关的单羟基保护中间体 | |
CN111892507B (zh) | 一种盐酸多巴胺的合成方法 | |
CN109503513B (zh) | 一种非布司他中间体的“一锅法”合成方法 | |
KR100434991B1 (ko) | N-메틸-n'-니트로구아니딘의 제조 방법 | |
CN115010676A (zh) | 一种4,5-二甲基-3-氨基异噁唑的制备方法和应用 | |
CN108752184B (zh) | 一种sglt2抑制剂中间体的制备方法 | |
CN114315609B (zh) | 一种制备顺式2-氨基环己醇的工艺方法 | |
CN111574458B (zh) | 一种麦角硫因的合成方法 | |
CN103087090B (zh) | 一种二棕榈酰基磷脂酰乙醇胺的合成方法 | |
CN105348101A (zh) | 一种对氯肉桂酸甲酯的制备方法 | |
CN115417797A (zh) | 一种联苯肼酯的制备方法 | |
CN112110879B (zh) | 一种舒欣啶游离碱的制备方法 | |
CN111574384B (zh) | 一种手性1-氨基-2-丙醇的制备方法 | |
CN109232222B (zh) | 一种(e)-辛-4-烯-1,8-二酸的制备方法 | |
WO2016078584A1 (zh) | 恩曲他滨的纯化方法 | |
CN113072514A (zh) | 轮环藤宁及其中间体的制备方法 | |
CN111217709A (zh) | 一种(1-氟环丙基)甲胺盐酸盐的制备方法 | |
CN109438243B (zh) | 一种电子级没食子酸辛酯的制备方法 | |
CN114790135B (zh) | 一种苯甲酰甲酸的制备方法 | |
CN115477653B (zh) | 一种曲拉西利关键中间体及曲拉西利的制备方法 | |
EA036663B1 (ru) | Способ получения азоксистробина | |
CN112812029B (zh) | 苯巴豆酸酯类化合物的制备方法 | |
CN116947691B (zh) | 一种马来酸氟伏沙明的制备方法 | |
CN114213261B (zh) | 一种4-甲氧基-2-硝基苯胺的制备方法 | |
CN109665967B (zh) | 茚类化合物不对称环氧化反应用配体及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220906 |
|
RJ01 | Rejection of invention patent application after publication |